Abstract 16478: ProBNP Strongly Predicts Future Vascular Events in Angiographied Coronary Patients With as Well as in Those Without the Metabolic Syndrome
Introduction: Pro-B-type natriuretic peptide (proBNP) is a prognostic biomarker in various patient populations.
Hypothesis: We aimed at testing the hypothesis that proBNP is a marker to predict cardiovascular events in metabolic syndrome (MetS) patients undergoing coronary angiography.
Methods: We therefore measured serum proBNP in 752 patients who underwent coronary angiography for the evaluation of suspected or established coronary artery disease (CAD). Significant CAD was diagnosed in the presence of coronary stenoses with lumen narrowing ≥50%. Presence of the MetS was defined according to the current harmonized consensus definition. Prospectively, we recorded vascular events over 5.1±2.4 years.
Results: ProBNP was significantly higher in patients with (n=591) than in subjects without significant CAD at baseline (715±1361 vs. 652±1842 pg/ml; p=0.003). Prospectively, we recorded 185 cardiovascular events. The incidence of vascular events significantly increased over tertiles of proBNP in patients with the MetS (15.8%, 24.2%, and 60.0% respectively; p=0.033) as well as in subjects without the MetS (13.3%, 22.2%, and 64.4%, respectively; p=0.004). Concordantly, serum proBNP significantly predicted the incidence of cardiovascular events after adjustment for age, gender, BMI, smoking, systolic and diastolic blood pressure, LDL cholesterol, HDL cholesterol and the eGFR both in patients with the MetS (standardized adjusted HR 1.34 [1.14-1.58]; p<0.001) and in subjects without the MetS (HR 1.24 [1.11-1.39]; p<0.001). These results were not attenuated after further adjustment for the angiographically determined baseline CAD state in patients with the MetS nor in subjects without the MetS (HRs 1.34 [1.14-1.57]; p<0.001 and 1.42 [1.24-1.63]; p<0.001, respectively).
Conclusions: We conclude that serum proBNP predicts cardiovascular events independently of established cardiovascular risk factors and of the baseline CAD state both in patients with and in subjects without the MetS.
Author Disclosures: P. Rein: None. D. Zanolin: None. A. Leiherer: None. A. Vonbank: None. C.H. Saely: None. H. Drexel: None.
- © 2016 by American Heart Association, Inc.